IAM
Iambic Therapeutics, Inc.
Price Chart
Latest Quote
$14.53
+0.12 (+0.83%)
Current Price
| Previous Close | $14.41 |
| Open | $14.41 |
| Day High | $14.90 |
| Day Low | $13.95 |
| Volume | 191,644 |
Stock Information
| Shares Outstanding | 47.40M |
| Total Debt | $5.23M |
| Cash Equivalents | $207.88M |
| Revenue | $18.25M |
| Net Income | $-94.25M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $688.73M |
| EPS (TTM) | $-2.69 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $531.54M |
| Sales | $18.25M |
| Income | $-94.25M |
| Book/sh | $-9.85 |
| Cash/sh | $4.39 |
| Employees | 171 |
Financial Ratios
| Quick Ratio | 4.51 |
| Current Ratio | 4.59 |
| Debt/Eq | 3.24 |
Returns & Margins
| Operating Margin | -419.59% |
Ownership
| Insider Ownership | 7.63% |
| Institutional Ownership | 17.32% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 37.74 |
| P/B | -1.47 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 2.46M |
Performance History
| Week | -9.24% |
| YTD | -23.16% |
| 10 Years | -23.16% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $14.53 | 191,644 |
| 2026-10-26 | $14.41 | 149,000 |
| 2026-10-23 | $14.26 | 609,600 |
| 2026-10-22 | $14.67 | 495,900 |
| 2026-10-21 | $15.80 | 478,900 |
| 2026-10-20 | $16.01 | 980,600 |
| 2026-10-19 | $16.34 | 2,382,700 |
| 2026-10-16 | $23.81 | 2,964,900 |
| 2026-10-15 | $18.91 | 2,009,400 |
About Iambic Therapeutics, Inc.
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on IAM.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $9,426,000 | $1,194,000 |
| Operating Revenue | $9,426,000 | $1,194,000 |
| Expenses | ||
| Interest Expense | $17,000 | $8,000 |
| Total Expenses | $91,776,000 | $55,071,000 |
| Other Income Expense | $-90,000 | - |
| Other Non Operating Income Expenses | $-90,000 | - |
| Net Non Operating Interest Income Expense | $5,190,000 | $6,034,000 |
| Interest Expense Non Operating | $17,000 | $8,000 |
| Operating Expense | $91,776,000 | $55,071,000 |
| General And Administrative Expense | $14,248,000 | $9,375,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-77,295,000 | $-47,877,000 |
| Net Interest Income | $5,190,000 | $6,034,000 |
| Interest Income | $5,207,000 | $6,042,000 |
| Normalized Income | $-77,295,000 | $-47,877,000 |
| Net Income From Continuing And Discontinued Operation | $-77,295,000 | $-47,877,000 |
| Total Operating Income As Reported | $-82,350,000 | $-53,877,000 |
| Net Income Common Stockholders | $-77,295,000 | $-47,877,000 |
| Net Income | $-77,295,000 | $-47,877,000 |
| Net Income Including Noncontrolling Interests | $-77,295,000 | $-47,877,000 |
| Net Income Continuous Operations | $-77,295,000 | $-47,877,000 |
| Pretax Income | $-77,250,000 | $-47,843,000 |
| Interest Income Non Operating | $5,207,000 | $6,042,000 |
| Operating Income | $-82,350,000 | $-53,877,000 |
| Per Share | ||
| Diluted EPS | $-2.24 | $-1.27 |
| Basic EPS | $-2.24 | $-1.27 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-76,008,000 | $-46,776,000 |
| Reconciled Depreciation | $1,225,000 | $1,059,000 |
| EBITDA (Bullshit earnings) | $-76,008,000 | $-46,776,000 |
| EBIT | $-77,233,000 | $-47,835,000 |
| Diluted Average Shares | $34,447,409 | $37,736,676 |
| Basic Average Shares | $34,447,409 | $37,736,676 |
| Diluted NI Availto Com Stockholders | $-77,295,000 | $-47,877,000 |
| Tax Provision | $45,000 | $34,000 |
| Research And Development | $77,528,000 | $45,696,000 |
| Selling General And Administration | $14,248,000 | $9,375,000 |
| Other Gand A | $6,368,000 | $4,716,000 |
| Salaries And Wages | $7,880,000 | $4,659,000 |
Fetched: 2026-10-27
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-186,563,000 | $-112,247,000 |
| Total Assets | $195,018,000 | $155,749,000 |
| Total Non Current Assets | $11,428,000 | $11,882,000 |
| Other Non Current Assets | $1,579,000 | $1,360,000 |
| Current Assets | $183,590,000 | $143,867,000 |
| Other Current Assets | $1,734,000 | $1,844,000 |
| Receivables | $1,317,000 | $444,000 |
| Accounts Receivable | $1,317,000 | $444,000 |
| Cash Cash Equivalents And Short Term Investments | $180,539,000 | $141,579,000 |
| Cash And Cash Equivalents | $180,539,000 | $141,579,000 |
| Debt | ||
| Total Debt | $5,653,000 | $6,497,000 |
| Long Term Debt And Capital Lease Obligation | $4,879,000 | $5,749,000 |
| Current Debt And Capital Lease Obligation | $774,000 | $748,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $381,581,000 | $267,996,000 |
| Total Non Current Liabilities Net Minority Interest | $355,292,000 | $251,108,000 |
| Non Current Deferred Liabilities | $9,081,000 | $2,701,000 |
| Current Liabilities | $26,289,000 | $16,888,000 |
| Other Current Liabilities | $805,000 | $307,000 |
| Current Deferred Liabilities | $11,305,000 | $6,638,000 |
| Payables And Accrued Expenses | $8,376,000 | $6,762,000 |
| Payables | $3,322,000 | $2,881,000 |
| Accounts Payable | $3,322,000 | $2,881,000 |
| Equity | ||
| Common Stock Equity | $-186,563,000 | $-112,247,000 |
| Total Equity Gross Minority Interest | $-186,563,000 | $-112,247,000 |
| Stockholders Equity | $-186,563,000 | $-112,247,000 |
| Gains Losses Not Affecting Retained Earnings | $24,000 | $7,000 |
| Other Equity Adjustments | $24,000 | $7,000 |
| Retained Earnings | $-195,180,000 | $-117,885,000 |
| Preferred Securities Outside Stock Equity | $341,332,000 | $242,658,000 |
| Other | ||
| Ordinary Shares Number | $47,400,796 | $47,400,796 |
| Share Issued | $47,400,796 | $47,400,796 |
| Tangible Book Value | $-186,563,000 | $-112,247,000 |
| Invested Capital | $-186,563,000 | $-112,247,000 |
| Working Capital | $157,301,000 | $126,979,000 |
| Capital Lease Obligations | $5,653,000 | $6,497,000 |
| Total Capitalization | $-186,563,000 | $-112,247,000 |
| Additional Paid In Capital | $8,571,000 | $5,610,000 |
| Capital Stock | $22,000 | $21,000 |
| Common Stock | $22,000 | $21,000 |
| Non Current Deferred Revenue | $9,081,000 | $2,701,000 |
| Long Term Capital Lease Obligation | $4,879,000 | $5,749,000 |
| Current Deferred Revenue | $11,305,000 | $6,638,000 |
| Current Capital Lease Obligation | $774,000 | $748,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,029,000 | $2,433,000 |
| Current Accrued Expenses | $5,054,000 | $3,881,000 |
| Net PPE | $9,849,000 | $10,522,000 |
| Accumulated Depreciation | $-3,885,000 | $-2,749,000 |
| Gross PPE | $13,734,000 | $13,271,000 |
| Leases | $25,000 | $73,000 |
| Construction In Progress | $0 | $58,000 |
| Other Properties | $13,505,000 | $13,008,000 |
| Machinery Furniture Equipment | $204,000 | $132,000 |
| Properties | $0 | $0 |
Fetched: 2026-10-27
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-60,103,000 | $-34,267,000 |
| Operating Activities | ||
| Operating Cash Flow | $-58,823,000 | $-33,560,000 |
| Cash Flow From Continuing Operating Activities | $-58,823,000 | $-33,560,000 |
| Operating Gains Losses | $50,000 | $-5,000 |
| Investing Activities | ||
| Capital Expenditure | $-1,280,000 | $-707,000 |
| Investing Cash Flow | $-1,280,000 | $-707,000 |
| Cash Flow From Continuing Investing Activities | $-1,280,000 | $-707,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $99,158,000 | $65,008,000 |
| Financing Cash Flow | $99,063,000 | $64,993,000 |
| Cash Flow From Continuing Financing Activities | $99,063,000 | $64,993,000 |
| Net Preferred Stock Issuance | $98,674,000 | $64,971,000 |
| Preferred Stock Issuance | $98,674,000 | $64,971,000 |
| Net Common Stock Issuance | $484,000 | $37,000 |
| Common Stock Issuance | $484,000 | $37,000 |
| Other | ||
| Repayment Of Debt | $-95,000 | $-15,000 |
| Interest Paid Supplemental Data | $17,000 | $5,000 |
| Income Tax Paid Supplemental Data | $45,000 | $34,000 |
| End Cash Position | $180,539,000 | $141,579,000 |
| Beginning Cash Position | $141,579,000 | $110,853,000 |
| Changes In Cash | $38,960,000 | $30,726,000 |
| Net Issuance Payments Of Debt | $-95,000 | $-15,000 |
| Net Long Term Debt Issuance | $-95,000 | $-15,000 |
| Long Term Debt Payments | $-95,000 | $-15,000 |
| Net PPE Purchase And Sale | $-1,280,000 | $-707,000 |
| Purchase Of PPE | $-1,280,000 | $-707,000 |
| Change In Working Capital | $13,569,000 | $10,355,000 |
| Change In Other Working Capital | $9,843,000 | $8,759,000 |
| Change In Other Current Liabilities | $0 | $-8,000 |
| Change In Other Current Assets | $-219,000 | $-755,000 |
| Change In Payables And Accrued Expense | $4,708,000 | $4,136,000 |
| Change In Accrued Expense | $4,267,000 | $3,856,000 |
| Change In Payable | $441,000 | $280,000 |
| Change In Account Payable | $441,000 | $280,000 |
| Change In Prepaid Assets | $110,000 | $-1,333,000 |
| Change In Receivables | $-873,000 | $-444,000 |
| Other Non Cash Items | $1,150,000 | $1,255,000 |
| Stock Based Compensation | $2,478,000 | $1,653,000 |
| Depreciation Amortization Depletion | $1,225,000 | $1,059,000 |
| Depreciation And Amortization | $1,225,000 | $1,059,000 |
| Net Foreign Currency Exchange Gain Loss | $17,000 | $-5,000 |
| Gain Loss On Sale Of PPE | $33,000 | $0 |
| Net Income From Continuing Operations | $-77,295,000 | $-47,877,000 |
Fetched: 2026-10-27